As both type 1 and type 2 diabetes are diseases where deficiency in β cell mass and function is pathogenic, the ability of thyroid hormone to preserve islet mass without loss of β cell differentiated function makes T3 an attractive factor for future therapies for diabetes. This evidence concerns the gene TG and type 2 diabetes mellitus.